Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1995 Nov 15;153(10):1437–1443.

Recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan.

B Habbick 1, M J Baker 1, M McNutt 1, D W Cockcroft 1
PMCID: PMC1487449  PMID: 7585370

Abstract

OBJECTIVE: To examine recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids for the treatment of asthma among Saskatchewan residents and to determine whether these trends are in keeping with widely publicized guidelines recommending a reduction in the use of agents to treat symptoms (i.e., inhaled beta 2-adrenergic agonists) and increased use of prophylactic agents (i.e., inhaled corticosteroids). DESIGN: Descriptive pharmacoepidemiologic study conducted with the use of data from the computerized database of the Saskatchewan Prescription Drug Plan. SETTING: Saskatchewan. PATIENTS: Saskatchewan residents 5 to 54 years of age who received one or more outpatient prescriptions for drugs to treat asthma (inhaled drugs, ingested beta 2-adrenergic agonists and ingested methylxanthines) from 1989 to 1993. OUTCOME MEASURES: Epidemiologic trends, calculated for each year: number of prescriptions per 1,000 persons; number of patients who received prescriptions for inhaled corticosteroids, inhaled beta 2-adrenergic agonists and any type of drug to treat asthma; mean number of such prescriptions per patient; and weighted mean amount of salbutamol, fenoterol and beclomethasone dispensed per patient. RESULTS: There has been an increase in the proportion of the population receiving prescriptions for drugs to treat asthma. The number of patients receiving these drugs per 1,000 people rose during the study period from 33.38 to 46.59 for any drug to treat asthma, from 24.70 to 33.77 for inhaled beta 2-adrenergic agonists and from 6.1 to 19.9 for inhaled corticosteroids. The mean number of prescriptions per patient decreased steadily for all drugs to treat asthma (from 5.34 in 1989 to 3.88 in 1993), for inhaled beta 2-adrenergic agonists (from 4.35 to 3.09) and for inhaled corticosteroids (from 2.98 to 2.25). The weighted mean amount of inhaled salbutamol dispensed per patient per year decreased by 40%, from 178.08 mg in 1989 to 109.14 mg in 1993. The weighted amount of fenoterol dispensed per patient per year declined even more, by 58%, from 387.91 mg in 1989 to 164.00 mg in 1993. Conversely, the weighted amount of inhaled beclomethasone dispensed per patient per year increased by 35% from 46.95 mg in 1989 to 63.50 mg in 1992, then dropped to 56.17 mg per year in 1993. CONCLUSION: These data demonstrate a substantial change in Saskatchewan in the prescribing of drugs to treat asthma; they suggest that many physicians responded to current guidelines advocating increased attention to prevention of airway inflammation in the treatment of asthma.

Full text

PDF
1437

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes P. J. A new approach to the treatment of asthma. N Engl J Med. 1989 Nov 30;321(22):1517–1527. doi: 10.1056/NEJM198911303212206. [DOI] [PubMed] [Google Scholar]
  2. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., Ball M., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet. 1989 Apr 29;1(8644):917–922. doi: 10.1016/s0140-6736(89)92505-1. [DOI] [PubMed] [Google Scholar]
  3. Ernst P., Habbick B., Suissa S., Hemmelgarn B., Cockcroft D., Buist A. S., Horwitz R. I., McNutt M., Spitzer W. O. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis. 1993 Jul;148(1):75–79. doi: 10.1164/ajrccm/148.1.75. [DOI] [PubMed] [Google Scholar]
  4. Ernst P., Spitzer W. O., Suissa S., Cockcroft D., Habbick B., Horwitz R. I., Boivin J. F., McNutt M., Buist A. S. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA. 1992 Dec 23;268(24):3462–3464. [PubMed] [Google Scholar]
  5. Hargreave F. E., Dolovich J., Newhouse M. T. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol. 1990 Jun;85(6):1098–1111. doi: 10.1016/0091-6749(90)90056-a. [DOI] [PubMed] [Google Scholar]
  6. Jeffery P. K., Wardlaw A. J., Nelson F. C., Collins J. V., Kay A. B. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis. 1989 Dec;140(6):1745–1753. doi: 10.1164/ajrccm/140.6.1745. [DOI] [PubMed] [Google Scholar]
  7. Pearce N., Crane J., Burgess C., Beasley R., Jackson R. Fenoterol and asthma mortality. Lancet. 1989 May 27;1(8648):1196–1197. doi: 10.1016/s0140-6736(89)92768-2. [DOI] [PubMed] [Google Scholar]
  8. Pearce N., Grainger J., Atkinson M., Crane J., Burgess C., Culling C., Windom H., Beasley R. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax. 1990 Mar;45(3):170–175. doi: 10.1136/thx.45.3.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rebuck A. S., Chapman K. R. Asthma: 2. Trends in pharmacologic therapy. CMAJ. 1987 Mar 1;136(5):483–488. [PMC free article] [PubMed] [Google Scholar]
  10. Sears M. R., Taylor D. R. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf. 1994 Oct;11(4):259–283. doi: 10.2165/00002018-199411040-00005. [DOI] [PubMed] [Google Scholar]
  11. Shoham Z., Katz A., Lancet M. Gore-Tex surgical membrane. Fertil Steril. 1989 Jun;51(6):1071–1072. doi: 10.1016/s0015-0282(16)60755-0. [DOI] [PubMed] [Google Scholar]
  12. Spitzer W. O., Suissa S., Ernst P., Horwitz R. I., Habbick B., Cockcroft D., Boivin J. F., McNutt M., Buist A. S., Rebuck A. S. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992 Feb 20;326(8):501–506. doi: 10.1056/NEJM199202203260801. [DOI] [PubMed] [Google Scholar]
  13. Stafford C. T. New concepts in chronic asthma. What is the impact on therapy? Postgrad Med. 1988 Sep 15;84(4):85-6, 91-6, 98. doi: 10.1080/00325481.1988.11700424. [DOI] [PubMed] [Google Scholar]
  14. Suissa S., Ernst P., Boivin J. F., Horwitz R. I., Habbick B., Cockroft D., Blais L., McNutt M., Buist A. S., Spitzer W. O. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):604–610. doi: 10.1164/ajrccm.149.3.8118625. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES